Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Elite Pharma Inc (ELTP) OTHER OTC

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 151,520
  • Shares Outstanding, K 733,720
  • Annual Sales, $ 12,500 K
  • Annual Income, $ -680 K
  • 36-Month Beta 0.30
  • Price/Sales 12.12
  • Price/Book 5.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1333 +20.03%
on 12/19/16
0.1829 -12.52%
on 12/23/16
+0.0190 (+13.48%)
since 12/13/16
3-Month
0.1280 +25.00%
on 11/10/16
0.1829 -12.52%
on 12/23/16
+0.0250 (+18.52%)
since 10/13/16
52-Week
0.1100 +45.45%
on 07/27/16
0.3950 -59.49%
on 07/13/16
-0.1651 (-50.78%)
since 01/13/16

Most Recent Stories

More News
Elite Provides Update on SequestOx(TM) New Drug Application

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the Company met with the U.S. Food and Drug Administration (the "FDA") on December 21, 2016 for an end-of-review meeting...

Elite Pharmaceuticals Files ANDA for Hydrocodone and Acetaminophen Combo

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic...

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2017 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the six months...

Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 2nd Quarter 2017 Financial Results on November 10, 2016

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that...

Elite Announces Development and License Agreement with SunGen Pharma LLC

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into...

Elite Announces Development and License Agreement with SunGen Pharma LLC

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into...

Elite Pharmaceuticals files ANDA to Market Generic Percocet

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic...

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2017 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the three months...

$200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore

MIAMI, FL / ACCESSWIRE / February 10, 2016 / $200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore. CD International Enterprises, Inc. (OTCPK: CDII), a U.S.-based company that sources...

Elite Pharmaceuticals generates higher consolidated revenues of USD2.2m for Q3 fiscal 2016

Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Tuesday that it recorded consolidated revenues of USD2.2m for the quarter ended 31 December 2015, the third quarter of its 2016 fiscal...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Support & Resistance

2nd Resistance Point 0.1700
1st Resistance Point 0.1650
Last Price 0.1600
1st Support Level 0.1550
2nd Support Level 0.1500

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.